Global Drug-Eluting Stents Market Size, Share, Trends & Growth Research Report 2024-2032

• The global drug-eluting stents market size reached USD 8.3 Billion in 2023.
• The market is expected to reach USD 13.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.51% during 2024-2032.
• North America leads the market, accounting for the largest drug-eluting stents market share.
• Polymer free coating accounts for the majority of the market share in the coating segment because they have the capacity to lessen inflammation and the likelihood of long-term issues.
• Based on the drug, the market is segmented into sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, and others.
• Cobalt-chromium holds the largest share in the drug-eluting stents industry.
• On the basis of the generation, the market is classified into 1st generation, 2nd generation, 3rd generation, and 4th generation.
• Coronary artery disease remains a dominant segment in the market, as it is among the most common cardiovascular diseases (CVD) that call for the use of drug-eluting stents.
• Hospitals represent the leading end-user segment.
• The increasing focus on patient-centered care and personalized medicine, which encourages the development of tailored stent solutions that cater to individual patient needs and conditions, is supporting the market growth.
• Besides this, the expansion of healthcare infrastructure in emerging markets, where improving access to advanced medical technologies is leading to greater adoption of drug-eluting stents for treating CVD.

Request to Get the Sample Report: https://www.imarcgroup.com/drug-eluting-stents-market/requestsample

Industry Trends and Drivers:

• The Increasing Prevalence of Cardiovascular Diseases (CVD):

The increasing prevalence of CVD significantly influences the drug-eluting stents market. Cardiovascular diseases, including coronary artery disease (CAD), are among the leading causes of morbidity and mortality globally. The rise in lifestyle-related risk factors, such as obesity, hypertension, diabetes, and smoking, has led to a higher incidence of these conditions. As populations age, the demand for effective interventions to treat coronary artery blockages has intensified.

Drug-eluting stents (DES) play a critical role in treating these conditions by releasing medication that helps prevent restenosis (the re-narrowing of blood vessels) after angioplasty procedures. With the global aging population and the growing burden of CVD, healthcare providers are increasingly relying on DES to enhance patient outcomes, thereby strengthening the market growth.

• Advancements in Stent Technology and Design:

Over the years, innovations have led to the development of stents with improved biocompatibility, drug formulations, and delivery systems. Modern drug-eluting stents are designed to minimize complications, such as thrombosis (blood clot formation) and late restenosis. Newer stents often feature biodegradable polymers and novel drugs that enhance therapeutic efficacy while reducing adverse effects.

Additionally, the integration of advanced imaging and deployment technologies has made it easier for clinicians to accurately position stents, further enhancing procedural success rates. The continuous evolution of stent technology, focusing on safety and effectiveness, is attracting more healthcare providers to adopt drug-eluting stents, contributing to market expansion.

• The Rising Demand for Minimally Invasive Procedures:

Minimally invasive techniques, such as percutaneous coronary intervention (PCI), offer patients the advantages of reduced recovery times, less postoperative pain, and lower risk of complications compared to traditional surgical options. DES are integral to these procedures, allowing for effective treatment of coronary artery blockages without the need for invasive surgeries.

As patients increasingly prefer outpatient procedures that minimize hospital stays and promote quicker recoveries, the adoption of DES in clinical practice has grown. Furthermore, healthcare systems are prioritizing cost-effective treatments that improve patient experiences, which aligns with the benefits offered by minimally invasive interventions involving drug-eluting stents, thereby bolstering the market expansion.

Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=4815&flag=C

Drug-Eluting Stents Market Report Segmentation:

Breakup By Coating:

• Polymer Based Coating
• Polymer Free Coating

Polymer-free coatings account for the majority of shares due to their ability to reduce inflammation and lower the risk of long-term complications.

Breakup By Drug:

• Sirolimus
• Paclitaxel
• Zotarolimus
• Everolimus
• Biolimus
• Others

Based on the drug, the market is segmented into sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, and others.

Breakup By Steel Platform:

• Stainless-steel
• Cobalt-Chromium
• Platinum-Chromium
• Nitinol
• Others

Cobalt-chromium dominates the market because of its superior strength, flexibility, and compatibility with thinner struts, which enhance patient outcomes.

Breakup By Generation:

• 1st Generation
• 2nd Generation
• 3rd Generation
• 4th Generation

On the basis of the generation, the market is classified into 1st generation, 2nd generation, 3rd generation, and 4th generation.

Breakup By Application:

• Coronary Artery Disease
• Peripheral Artery Disease

Coronary artery disease holds the majority of shares as it is one of the most prevalent cardiovascular conditions requiring drug-eluting stent interventions.

Breakup By End User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Hospitals represent the majority of shares as they are primary centers for performing complex cardiovascular procedures like stent placement.

Breakup By Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America holds the leading position due to the advanced healthcare infrastructure and high prevalence of cardiovascular diseases in the region.

Top Drug-Eluting Stents Market Leaders: The drug-eluting stents market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies.

Some of the key players in the market are:

• Abbott Laboratories
• B. Braun Melsungen AG
• Biosensors International Group Ltd.
• Biotronik
• Boston Scientific Corporation
• Cardinal Health Inc.
• Cook Medical LLC (Cook Group Incorporated)
• Lepu Medical Technology (Beijing) Co. Ltd.
• Medtronic plc
• MicroPort Scientific Corporation
• Sino Medical Sciences Technology Inc.
• Terumo Corporation

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1–631–791–1145